Advanced Clinical Research Institute | Tampa, FL

Research site

(Unclaimed)

Location

4164 N Armenia Ave, tampa, Florida, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

Risankizumab

Lutikizumab

ABBV-157

ANB019

SCD-044

EVO756

Cedirogant

Imsidolimab

EP262

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 18 total trials

A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria

This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism...

Active, not recruiting

Chronic Inducible Urticaria

Drug: Oral EVO756

A Study of Barzolvolimab in Patients With Prurigo Nodularis

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling

Prurigo Nodularis

Other: Matching Placebo

Biological: barzolvolimab

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up)

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Active, not recruiting

Vitiligo

Drug: Upadacitinib

Other: NB-UVB (narrow-band ultraviolet B) Phototherapy

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (Intrepid)

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling

Hidradenitis Suppurativa

Drug: Lutikizumab

Drug: Placebo

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Enrolling

Atopic Dermatitis

Drug: Placebo

Drug: Lutikizumab

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Active, not recruiting

Alopecia Areata

Drug: Upadacitinib

Drug: Placebo

A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) (IMMpactful)

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting

Moderate Plaque Psoriasis

Drug: Risankizumab

Drug: Deucravacitinib

Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe...

Active, not recruiting

Atopic Dermatitis

Biological: Placebo

Biological: OpSCF

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 (OptIMMize-2)

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This...

Invitation-only

Psoriasis

Drug: Risankizumab